Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study.

Oliver, R; Krueger, J G; Glatt, S; Vajjah, P; Mistry, C; Page, M; Edwards, H; Garcet, S; Li, X; Dizier, B; Maroof, A; Watling, M; El Baghdady, A; Baeten, D; Ionescu, L; Shaw, S

Oliver, R; Krueger, J G; Glatt, S; Vajjah, P; Mistry, C; Page, M; Edwards, H; Garcet, S; Li, X; Dizier, B; Maroof, A; Watling, M; El Baghdady, A; Baeten, D; Ionescu, L; Shaw, S.

Affiliation

Oliver R; UCB Pharma, Slough, UK.
Krueger JG; The Rockefeller University, New York, NY, USA.
Glatt S; UCB Pharma, Slough, UK.
Vajjah P; UCB Pharma, Slough, UK.
Mistry C; UCB Pharma, Slough, UK.
Page M; Veramed, London, UK.
Edwards H; UCB Pharma, Slough, UK.
Garcet S; UCB Pharma, Slough, UK.
Li X; The Rockefeller University, New York, NY, USA.
Dizier B; The Rockefeller University, New York, NY, USA.
Maroof A; UCB Pharma, Braine-l'Alleud, Belgium.
Watling M; UCB Pharma, Slough, UK.
El Baghdady A; UCB Pharma, Brussels, Belgium.
Baeten D; Institute of Pharmaceutical Science, King's College London, London, UK.
Ionescu L; UCB Pharma, Slough, UK.
Shaw S; UCB Pharma, Brussels, Belgium.

Br J Dermatol ; 186(4): 652-663, 2022 04.

Article in En | MEDLINE | ID: mdl-34687214

Subject(s)

Psoriasis; Transcriptome; Antibodies, Monoclonal, Humanized; Double-Blind Method; Humans; Psoriasis/drug therapy; Psoriasis/genetics; Severity of Illness Index; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / Transcriptome Type of study: Clinical_trials Limits: Humans Language: En Journal: Br J Dermatol Year: 2022 Type: Article Affiliation country: United kingdom

Fulltext

XML

PubMed Links

Search on Google